

해외 바이오의약품 임상 현황 (2020.2.24~2020.3.1)

한국바이오의약품협회, 2020.3.3.
출처: ClinicalTrials.gov

미국 88건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04285671	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Necitumumab Drug: Osimertinib Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Trastuzumab	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Eli Lilly and Company Genentech, Inc.	Phase 1 Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleuce	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1 Phase 2
NCT04214418	Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTophagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies	Gastrointestinal Cancer	Drug: Cobimetinib Drug: Hydroxychloroquine Drug: Atezolizumab	Columbia University Genentech, Inc.	Phase 1 Phase 2
NCT04201821	Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women	Fecal Incontinence	Biological: fecal microbial transplantation (FMT)	University of Pennsylvania	Phase 1 Phase 2
NCT04193293	A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer	Head and Neck Squamous Cell Carcinoma	Drug: duvelisib Biological: pembrolizumab	Verastem, Inc.	Phase 1 Phase 2
NCT04108481	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Colorectal Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Liver Metastasis Colon Cancer Colo-rectal Cancer Colorectal Adenocarcinoma Colorectal Neoplasms Liver Metastases Colorectal Carcinoma	Drug: Durvalumab Radiation: Yttrium-90 RadioEmbolization	University of Iowa Biocompatibles UK Ltd AstraZeneca	Phase 1 Phase 2
NCT04093349	A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)	Pompe Disease Pompe Disease (Late-onset) Glycogen Storage Disease Type 2 Glycogen Storage Disease Type II LOPD Lysosomal Storage Diseases Acid Maltase Deficiency	Genetic: SPK-3006	Spark Therapeutics	Phase 1 Phase 2
NCT04074967	Study of ARRY-614 Plus Either Nivolumab or Ipilimumab	Renal Cell Carcinoma Melanoma Solid Tumor	Drug: Phase Ib ARRY-614 + nivolumab Drug: Phase Ib ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + nivolumab (melanoma) Drug: Phase II ARRY-614 + nivolumab (RCC)	Jason J. Luke, MD Array BioPharma University of Pittsburgh	Phase 1 Phase 2
NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	Melanoma	Biological: hu14.18-IL2 Radiation: Radiation Therapy Biological: Nivolumab Biological: Ipilimumab	University of Wisconsin, Madison National Cancer Institute (NCI) Bristol-Myers Squibb Apeiron Biologics Provenance Biopharmaceuticals	Phase 1 Phase 2
NCT03915431	A Study of NCS-01 in Patients With Acute Ischemic Stroke	Ischemic Stroke	Biological: NCS-01 Biological: Placebo	NC Medial Research Inc	Phase 1 Phase 2
NCT03597594	Haplocompatible Transplant Using TCR $\alpha\beta$ Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Severe Combined Immunodeficiency	Drug: Anti-thymocyte globulin (rabbit) Drug: Busulfan Drug: Fludarabine Drug: Thiotepa Device: CliniMACS Other: Donor Lymphocyte Infusion	St. Jude Children's Research Hospital	Phase 1 Phase 2
NCT03513458	Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	Asthma	Biological: Anakinra Other: Anakinra Matching Placebo Drug: Dermatophagoides Farinae	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 Phase 2
NCT04109482	Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDEN, AML, and hrMDS.	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDEN) Acute Myeloid Leukemia Relapsed or Refractory HRMDS	Biological: MB-102 Drug: Decitabine Drug: Fludarabine Drug: Cyclophosphamide	Mustang Bio	Phase 1 Phase 2
NCT04291079	SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors	Cancer	Biological: SRK-181 Biological: anti-PD-(L)1 antibody therapy	Scholar Rock, Inc.	Phase 1
NCT04290546	CIML NK Cell in Head & Neck Cancer	Squamous Cell Carcinoma of the Head and Neck Recurrent Head and Neck Squamous Cell Carcinoma	Drug: Interleukin-15 Superagonist (N-803) Biological: CIML NK cell Infusion Drug: Ipilimumab	Dana-Farber Cancer Institute Altor BioScience Bristol-Myers Squibb Miltenyi Biotec B.V. & Co. KG	Phase 1
NCT04287985	Phase 2 Study of VIS649 for IgA Nephropathy	Immunoglobulin A Nephropathy Glomerular Disease IgAN	Drug: Dose-Placebo Drug: Low Dose-VIS649 Drug: Medium Dose-VIS649 Drug: High Dose-VIS649	Visterra, Inc.	Phase 2
NCT04284293	CNS10-NPC for the Treatment of RP	Retinitis Pigmentosa	Biological: CNS10-NPC implantation	Cedars-Sinai Medical Center California Institute for Regenerative Medicine (CIRM)	Phase 1
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease	Drug: Fecal Microbiota Transplantation Capsule (OpenBiome FMT Capsule)	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04280328	Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Drug: CPI-444 Drug: daratumumab	Corvus Pharmaceuticals, Inc.	Phase 1
NCT04274166	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose)	Wake Forest University Health Sciences Novartis	Phase 2
NCT04270175	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab	Amyloid AL Amyloidosis Refractory AL Amyloidosis	Drug: Daratumumab Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2
NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab	Squamous Cell Lung Cancer Squamous Non-small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck	Biological: PANDA-VAC	UNC Lineberger Comprehensive Cancer Center	Phase 1
NCT04262167	Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Biological: Lung Spheroid Stem Cells 100 million Biological: Lung Spheroid Stem Cells 200 million	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
NCT04262154	Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer	Metastatic Prostate Cancer	Drug: Atezolizumab Drug: Abiraterone Drug: Prednisone Drug: Lupron	Memorial Sloan Kettering Cancer Center Genentech, Inc.	Phase 2
NCT04254419	Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas	High Grade Glioma	Biological: NK cells	Nationwide Children's Hospital	Phase 1

해외 바이오의약품 임상 현황 (2020.2.24~2020.3.1)

한국바이오의약품협회, 2020.3.3.
출처: ClinicalTrials.gov

NCT04251416	A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma	Endometrial Carcinoma	Drug: Sacituzumab Govitecan	Alessandro Santini Immunomedics, Inc. Yale University	Phase 2
NCT04248569	DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Fibrolamellar Hepatocellular Carcinoma (FLC)	Drug: DNAJB1-PRKACA peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04240808	Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)	Non Hodgkin Lymphoma	Biological: UCD19 CAR T Cells	University of Colorado, Denver	Phase 1
NCT04238091	Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata	Alopecia Areata Alopecia Totalis Alopecia Universalis	Drug: Fecal material transfer therapy Procedure: 4mm Punch Biopsy of Scalp Diagnostic Test: Blood draw Procedure: Skin Microbiome sampling Procedure: Hair Microbiome Sampling Drug: Pre-FMT Antibiotic Cocktail Drug: Bowel Prep	Columbia University	Phase 2
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Small Lymphocytic Lymphoma	Biological: Daratumumab Drug: Ibrutinib	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	Glioblastoma	Drug: INCMGA00012 Drug: INCAGN01876 Drug: SRS Procedure: Brain surgery	University of Pennsylvania Incyte Corporation	Phase 2
NCT04223765	Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma	Mantle Cell Lymphoma Follicular Lymphoma Splenic Marginal Zone Lymphoma Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Nodal Marginal Zone Lymphoma Indolent Non-hodgkin Lymphoma	Drug: CAR.k28 Drug: Fludarabine Drug: Cyclophosphamide Drug: Bendamustine	UNC Lineberger Comprehensive Cancer Center	Phase 1
NCT04214392	Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of Recurrent or Progressive Glioblastoma	Recurrent Glioblastoma Recurrent Malignant Glioma Recurrent WHO Grade II Glioma Recurrent WHO Grade III Glioma	Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYS	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04211714	Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure	Telomere Shortening Bone Marrow Failure	Biological: EXG34217	Elixirgen Therapeutics, Inc.	Phase 1
NCT04209686	Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Advanced Gastric Adenocarcinoma	Drug: Paclitaxel Drug: Olaparib Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme Corp.	Phase 2
NCT04199767	SMIFF Multi-Device Study 2	Mild Cognitive Impairment Cognitive Impairment	Drug: 20 IU Humulin R U-100 (NDC: 0002-8215, Eli Lilly & Company) Drug: 40 IU Humulin R U-100 (NDC: 0002-8215, Eli Lilly & Company)	Wake Forest University Health Sciences	Phase 2
NCT04190056	Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8	Biological: Pembrolizumab Drug: Tamoxifen Drug: Vorinostat	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2
NCT04189952	Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia Marginal Zone Lymphoma	Drug: Acalabrutinib Drug: Rituximab Drug: Ifosfamide Drug: Carboplatin Drug: Etoposide	University of Miami AstraZeneca	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04172987	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	Healthy	Drug: Tirzepatide Drug: EE/NGM	Eli Lilly and Company	Phase 1
NCT04160494	D2C7-IT With Atezolizumab for Recurrent Gliomas	Malignant Glioma	Drug: D2C7-IT (6920 ng/mL via convection-enhanced delivery) Drug: Atezolizumab (1200 mg every three weeks)	Darell Bigner Istari Oncology, Inc. National Cancer Institute (NCI) Genentech, Inc. Duke University	Phase 1
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison psen	Phase 2
NCT04149821	Umbralesib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy	Chronic Lymphocytic Leukemia CLL Progression CLL/SLL	Drug: Umbralesib Drug: Ublituximab	Weill Medical College of Cornell University TG Therapeutics, Inc.	Phase 2
NCT04136275	CAR-37 T Cells In Hematologic Malignancies	Hematologic Malignancy Leukemia Lymphoma Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin	Biological: CAR-37 T cells	Marcela V. Maus, M.D., Ph.D. Massachusetts General Hospital	Phase 1
NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	Human Papillomavirus Type 16 Cervical Intraepithelial Neoplasia Grade II Cervical Intraepithelial Neoplasia, Grade III	Drug: pNGVL4aCRTE6E7L2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Phase 1
NCT04123379	Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)	Non-small Cell Lung Cancer Hepatocellular Carcinoma	Drug: Nivolumab Drug: BMS-813160 Drug: BMS-986253	Icahn School of Medicine at Mount Sinai Bristol-Myers Squibb	Phase 2
NCT04117945	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	BRAF V600E Negative KRAS Gene Mutation Negative Locally Advanced Unresectable Colorectal Adenocarcinoma Metastatic Colorectal Adenocarcinoma NRAS Gene Mutation Negative Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVD Colorectal Cancer AJCC v8 Stage IVE Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Cetuximab Drug: Irinotecan Biological: Panitumumab Drug: Regorafenib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Colorectal Cancer Pancreatic Cancer	Drug: KRAS peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1

해외 바이오의약품 임상 현황 (2020.2.24~2020.3.1)

한국바이오의약품협회, 2020.3.3.
출처: ClinicalTrials.gov

NCT04116073	INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer	Pancreatic Cancer Non-resectable Pancreatic Cancer Metastatic	Drug: INCMGA00012 (PD-1 antibody)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Incyte Corporation	Phase 2
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04084080	Sickle Cell Disease and Cardiovascular Risk - Red Cell Exchange Trial (SCD-CARRE)	Sickle Cell Disease	Biological: Red Blood Cell Other: Standard of care	Mark Gladwin National Heart, Lung, and Blood Institute (NHLBI) University of Pittsburgh	Phase 3
NCT04077021	First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer	Castration-Resistant Prostatic Cancer	Drug: CCW702	Calibr, a division of Scripps Research	Phase 1
NCT04059757	Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD	Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)	Biological: Fecal Microbiota Transplantation (FMT)	Leland Metheny Case Comprehensive Cancer Center	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agiros Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04030052	Emicizumab PUPs and Nuwiq ITI Study	Hemophilia A	Drug: Nuwiq (low dose protocol) Drug: Emicizumab Drug: Nuwiq (Atlanta protocol)	Emory University	Phase 3
NCT04013672	Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence	Recurrent Glioblastoma	Drug: Pembrolizumab Drug: SurVaxM Drug: Sargramostim Drug: Montanide ISA 51	Manmeet Ahluwalia, MD Case Comprehensive Cancer Center	Phase 2
NCT04003246	Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer Lung Cancer Stage III	Radiation: Thoracic RT and Durvalumab Drug: Consolidative Durvalumab	University of Texas Southwestern Medical Center AstraZeneca	Phase 2
NCT03993327	An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody M5A Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03941769	Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant	Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Cord Blood Transplant Recipient Myelodysplastic Syndrome Myeloproliferative Neoplasm	Biological: Recombinant Interleukin-7	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT03920631	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas	B Cell Lymphomas	Drug: Nivolumab Biological: Microtransplantation	Ahmed Galal, MD Duke University	Phase 1
NCT03798301	Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells	CMV Infection Cytomegalovirus Infections CMV Viremia Opportunistic Infections	Biological: CMV-specific T-cells	University of Wisconsin, Madison University of Wisconsin Program for Advanced Cell Therapy (PACT) University of Wisconsin Carbone Cancer Center (UWCCC) University of Wisconsin School of Medicine and Public Health (UWSPH) UW Health	Phase 1
NCT03639324	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL	Chronic Lymphocytic Leukemia CLL Relapsed CLL Refractory Chronic Lymphocytic Leukemia Relapsed Chronic Lymphocytic Leukemia	Drug: Rituximab, Idelalisib, and Venetoclax	Virginia Commonwealth University	Phase 1
NCT03617445	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients	Clostridium Difficile Infection Recurrence	Drug: FMT enema Drug: Oral Vancomycin Drug: FMT enema placebo Drug: Oral Vancomycin placebo	University of Wisconsin, Madison	Phase 2
NCT03608631	Exosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation	KRAS NP_004976.2:p.G12D Metastatic Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia in Remission Blasts 5 Percent or Less of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Donor Minimal Residual Disease Myelodysplastic Syndrome Myelofibrosis Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Biological: Anti-Thymocyte Globulin Drug: Busulfan Drug: Cyclophosphamide Drug: Cyclosporine Drug: Fludarabine Phosphate Drug: Methotrexate Procedure: Peripheral Blood Stem Cell Transplantation Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT03579888	CD19-Specific T Cells Post AlloSCT	Acute Lymphoblastic Leukemia Blasts More Than 5 Percent of Bone Marrow Nucleated Cells Blasts More Than 5 Percent of Peripheral Blood White Cells CD19 Positive Chronic Lymphocytic Leukemia Minimal Residual Disease Non-Hodgkin Lymphoma Small Lymphocytic Lymphoma	Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells Drug: Cyclophosphamide Drug: Fludarabine	M.D. Anderson Cancer Center Ziopharm Oncology	Phase 1
NCT03508479	Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection	Healthy Volunteers Rhinovirus	Biological: RG-HRV16	University of North Carolina, Chapel Hill Environmental Protection Agency (EPA)	Phase 1
NCT03068832	Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Pediatric Brain Tumor	Biological: Personalized peptide vaccine Drug: Poly ICLC Procedure: Peripheral blood draw	Washington University School of Medicine	Phase 1
NCT04278144	A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors	Neoplasm, Metastatic Neoplasm, Breast Neoplasm, Gastric	Drug: BDC-1001 Drug: Pembrolizumab	Bolt Biotherapeutics, Inc.	Phase 1
NCT04227938	Study of ALPN-101 in Subjects With Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease	Graft Vs Host Disease	Drug: ALPN-101	Alpine Immune Sciences, Inc.	Phase 1

해외 바이오의약품 임상 현황 (2020.2.24~2020.3.1)

한국바이오의약품협회, 2020.3.3.
출처: ClinicalTrials.gov

NCT04212091	Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants	HIV Infections	Biological: PGT121.414.LS Biological: VRC07-523LS	National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network HIV Prevention Trials Network	Phase 1
NCT04160065	Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC	Merkel Cell Carcinoma Cutaneous Squamous Cell Carcinoma	Biological: IFx-Hu2.0	Morphogenesis, Inc. H. Lee Moffitt Cancer Center and Research Institute University of Southern California	Phase 1
NCT03774654	CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)	Refractory B-Cell Non-Hodgkin Lymphoma Refractory B-Cell Small Lymphocytic Lymphoma Relapsed Adult ALL Relapsed CLL Relapsed Non Hodgkin Lymphoma	Genetic: CD19.CAR-aNKT cells Drug: Cyclophosphamide Drug: Fludarabine	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System	Phase 1
NCT03690011	Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells	T-cell Acute Lymphoblastic Leukemia T-cell Acute Lymphoblastic Lymphoma T-non-Hodgkin Lymphoma	Genetic: CD7.CAR/28zeta CAR T cells Drug: Fludarabine Drug: Cytosine	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04251117	GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC	HCC	Biological: GNOS-PV02 Biological: INO-9012 Drug: Pembrolizumab Device: CELLECTRA 2000 EP Device	Geneos Therapeutics	Phase 1 Phase 2
NCT04250636	3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals	Human Immunodeficiency Virus	Drug: 3BNC117-LS Drug: 10-1074-LS	Rockefeller University National Institute of Allergy and Infectious Diseases (NIAID) Weill Medical College of Cornell University Perelman School of Medicine University of Pennsylvania	Phase 1
NCT04157127	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma	Pancreatic Adenocarcinoma Pancreatic Cancer	Biological: Autologous DC vaccine	Baylor College of Medicine Cancer Cures for Kids	Phase 1
NCT04270942	At-Risk for Type 1 Diabetes Extension Study	Diabetes Mellitus, Type 1	Biological: teplizumab	Provention Bio, Inc.	Phase 2
NCT04150965	Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT	Multiple Myeloma Relapsed Refractory Multiple Myeloma	Drug: Elotuzumab, pomalidomide, dexamethasone Drug: Anti-LAG-3 Drug: Anti-LAG-3 + Pomalidomide + Dexamethasone Drug: Anti-TIGIT Drug: Anti-TIGIT + Pomalidomide + Dexamethasone	Multiple Myeloma Research Consortium Bristol-Myers Squibb Emory University Washington University School of Medicine Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Atrium Health Mayo Clinic Memorial Sloan Kettering Cancer Center Icahn School of Medicine at Mount Sinai University of California, San Francisco	Phase 1 Phase 2
NCT04285567	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine	Hoffmann-La Roche	Phase 3
NCT04176120	Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)	Diabetic Foot Infection Non-healing Wound Non-healing Diabetic Foot Ulcer	Biological: TTAX01 Other: Standard Care	Tissue Tech Inc.	Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT04096950	Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury	Spinal Cord Injury	Biological: MT-3921 Low dose Biological: MT-3921 High dose	Mitsubishi Tanabe Pharma Development America, Inc.	Phase 1
NCT04004611	A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)	Ulcerative Colitis	Drug: Mirikizumab	Eli Lilly and Company	Phase 2
NCT04209660	Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Adenoid Cystic Carcinoma Salivary Gland Cancer	Drug: Lenvatinib Drug: Pembrolizumab	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme Corp. Eisai Inc.	Phase 2
NCT03937154	Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer	Chemotherapy-induced Thrombocytopenia	Drug: Romiplostim Drug: Placebo	Amgen	Phase 3
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04261023	Abatacept in Individuals Who are Considered At Risk of Developing Inflammatory Arthritis	Inflammatory Arthritis	Drug: Orencia 125 MG Per 1 ML Prefilled Syringe	University of Leeds	Phase 2
NCT04262427	The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And Pembrolizumab in Metastatic Renal Cell Carcinoma	Metastatic Renal Cell Carcinoma	Drug: Cyclophosphamide 50mg Drug: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]	The Christie NHS Foundation Trust Merck Sharp & Dohme Corp. Liverpool Clinical Trials Centre (LCTC), University of Liverpool University of Manchester	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2020.2.24~2020.3.1)

한국바이오의약품협회, 2020.3.3.
출처: ClinicalTrials.gov

○ 프랑스 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04180059	Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation	Haematologic Disease	Combination Product: CTL 19	Nantes University Hospital INSERM U01232 CRCINA	Phase 1
NCT04280848	Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma	Glioblastoma	Drug: UCPVax	Centre Hospitalier Universitaire de Besancon	Phase 1 Phase 2
NCT04217473	TNFAlpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma	Metastatic Melanoma	Biological: TILT-123	TILT Biotherapeutics Ltd.	Phase 1
NCT04169841	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	Immunotherapy	Drug: olaparib, durvalumab, tremelimumab	Centre Georges Francois Leclerc AstraZeneca	Phase 2
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2

○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04276207	A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps	Diabetes Mellitus, Type 1	Drug: LY900014 Drug: Insulin Lispro	Eli Lilly and Company	Phase 1
NCT04224636	Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	Hepatocellular Carcinoma Non-resectable	Combination Product: Atezolizumab Injection, Bevacizumab Injection	Ludwig-Maximilians - University of Munich	Phase 2
NCT04257448	Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.	Pancreas Cancer Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Drug: Romidepsin Drug: Azacitidine Drug: nab-Paclitaxel Drug: Gemcitabine Drug: Durvalumab Drug: Lenalidomide capsule	GWT-TUD GmbH Celgene AstraZeneca	Phase 1 Phase 2
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2
NCT04231981	Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)	Penile Cancer	Drug: INCMGA00012	MedSIR Incyte Corporation	Phase 2

○ 중국 12건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04286711	Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer	Advanced Gastric Cancer	Drug: Albumin-paclitaxel, Apatinib, Camrelizumab	China Medical University, China	Phase 1 Phase 2
NCT04276896	Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccines	Pathogen Infection SARS-CoV-2 Infection	Biological: Infusion of LV-DC Vaccine or Antigen-specific Cytotoxic T Cells	Shenzhen Geno-Immune Medical Institute	Phase 1 Phase 2
NCT04146298	Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer	Pancreatic Cancer Pancreatic Neoplasms Pancreatic Ductal Adenocarcinoma Advanced Cancer	Drug: Cyclophosphamide Drug: Fludarabine Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells Drug: Anti-PD-1 monoclonal antibody	Guo ShiWei Providence Cancer Center, Earle A. Chiles Research Institute Changhai Hospital	Phase 1 Phase 2
NCT04291781	A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy	IgA Nephropathy	Biological: RC18 160mg Biological: RC18 240mg Biological: placebo	RemeGen	Phase 2
NCT04284202	PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC	NSCLC Stage IV ARID1A PD-1	Drug: PD-1 plus Dasatinib	The Affiliated Hospital of Qingdao University	Phase 2
NCT04270461	NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors	Hepatocellular Carcinoma Glioblastoma Medulloblastoma Colon Cancer	Biological: NKG2D-based CAR T-cells	Jiujiang University Affiliated Hospital KAEDI	Phase 1
NCT04263870	Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction	Gastroesophageal Junction Adenocarcinoma Stomach Adenocarcinoma Locally Advanced Unresectable Gastric Adenocarcinoma Metastatic Gastric Cancer	Drug: sintilimab	Sichuan University	Phase 2
NCT04258644	Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer	Gastric Cancer	Drug: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1	Beijing Friendship Hospital	Phase 2
NCT04231292	A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis	Patient of Anemia in Chronic Renal Failure With Hemodialysis	Drug: RD01 Drug: Recombinant Human Erythropoiesis Injection (CHO cell) Drug: placebo	Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd	Phase 2
NCT04230187	Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer	Colorectal Cancer	Drug: mFOLFOXIRI plus Bevacizumab Drug: mFOLFOX6 Plus Bevacizumab	Yanhong Deng Sun Yat-sen University	Phase 3
NCT04291248	A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor	MSI-H or dMMR Advanced Solid Tumors	Drug: AK105 Drug: Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
NCT04236141	A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).	Diffuse, Large B-Cell, Lymphoma	Drug: Polatuzumab Vedotin Drug: Bendamustine Drug: Rituximab Drug: Placebo	Hoffmann-La Roche	Phase 3

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04276428	A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus	Diabetes Mellitus, Type 2	Drug: LY3209590 Drug: Insulin Degludec	Eli Lilly and Company	Phase 1
NCT04004611	A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)	Ulcerative Colitis	Drug: Mirikizumab	Eli Lilly and Company	Phase 2